FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2286645807> ?p ?o ?g. }

• W2286645807 abstract "B118 Background: Lapatinib is a small molecule reversible tyrosine kinase inhibitor of EGFR and ErbB2 that shows in vitro and in vivo activity against a range of EGFR- and ErbB2-dependent adult cancer cell lines and that has clinical efficacy against ErbB2-overexpressing breast cancer. Lapatinib was studied by the PPTP to develop data concerning the relevance of EGFR family members as therapeutic targets for childhood cancers.
 Methods: The PPTP includes a molecularly characterized in vitro panel of cell lines (n=27) and in vivo panel of xenografts (n=61) representing most of the common types of childhood solid tumors and childhood ALL. Lapatinib in vitro testing used media containing 20% FCS and evaluated concentrations from 1.0 nM to 10 µM, with viable cell numbers for treated and control replicates evaluated at 96 hours using the DIMSCAN fluorescence-based method. Lapatinib was tested against the PPTP in vivo panels using a twice-daily oral administration schedule for six weeks (5-days on, 2-days off) at a dose of 160 mg/kg (320 mg/kg/day). Three measures of antitumor activity were used: 1) response criteria modeled after the clinical setting; 2) treated to control (T/C) tumor volume at day 21; and 3) a time to event (4-fold increase in tumor volume) measure based on the median EFS of treated and control lines (intermediate activity required EFS T/C > 2, and high activity additionally required a net reduction in median tumor volume at the end of the experiment).
 Results: EGFR and/or ErbB2 were expressed at detectable levels in most of the PPTP’s cell lines and xenografts at the RNA level based upon data from Affymetrix U133 Plus 2.0 arrays. The median IC50 value for lapatinib against the entire PPTP cell line panel was 6.84 µM. IC50 values ranged from a low of 2.08 µM (Ramos, NHL) to a maximum exceeding 10.0 µM in seven cell lines. Lapatinib was well tolerated in vivo, with toxicity in only 1.5% of the treated animals. Lapatinib induced significant differences in EFS distribution compared to controls in 1 of 41 evaluable xenografts tested. No xenografts met the criteria for intermediate activity for the PPTP EFS activity measure (EFS T/C value > 2.0 and a significant difference in EFS distribution). No objective responses were observed in any of the solid tumor panels or in the ALL panel. The best response observed was a single example of PD2 (progressive disease with growth delay).
 Conclusions: The response of the PPTP cell lines to lapatinib corresponds to the pattern of response described previously for adult cancer cell lines that do not overexpress EGFR or ErbB2 and that have IC50 values exceeding 1 µM. Thus, the lapatinib in vitro activity against the PPTP cell lines likely represents “off-target” kinase inhibition effects. The lack of in vivo activity for lapatinib is consistent with previous reports that EGFR mutation and ErbB2 amplification are uncommon for childhood cancers. These results do not preclude a role for lapatinib in a biological subtype of a pediatric cancer that is not represented within the PPTP panel. However, when combined with preclinical and clinical experience to date for EGFR small molecule inhibitors, the results do suggest a limited role for EGFR family members as therapeutic targets for childhood cancers. (Supported by NCI NO1CM42216)" @default.
• W2286645807 created "2016-06-24" @default.
• W2286645807 creator A5005797590 @default.
• W2286645807 creator A5009981843 @default.
• W2286645807 creator A5020479274 @default.
• W2286645807 creator A5024547587 @default.
• W2286645807 creator A5025528414 @default.
• W2286645807 creator A5028049853 @default.
• W2286645807 creator A5032743242 @default.
• W2286645807 creator A5038533156 @default.
• W2286645807 creator A5046943976 @default.
• W2286645807 creator A5057371623 @default.
• W2286645807 creator A5066877678 @default.
• W2286645807 creator A5073277560 @default.
• W2286645807 creator A5080585542 @default.
• W2286645807 date "2007-11-01" @default.
• W2286645807 modified "2023-10-15" @default.
• W2286645807 title "Pediatric preclinical testing program (PPTP) evaluation of the EGFR and ErbB2 inhibitor lapatinib" @default.
• W2286645807 hasPublicationYear "2007" @default.
• W2286645807 type Work @default.
• W2286645807 sameAs 2286645807 @default.
• W2286645807 citedByCount "1" @default.
• W2286645807 countsByYear W22866458072013 @default.
• W2286645807 crossrefType "journal-article" @default.
• W2286645807 hasAuthorship W2286645807A5005797590 @default.
• W2286645807 hasAuthorship W2286645807A5009981843 @default.
• W2286645807 hasAuthorship W2286645807A5020479274 @default.
• W2286645807 hasAuthorship W2286645807A5024547587 @default.
• W2286645807 hasAuthorship W2286645807A5025528414 @default.
• W2286645807 hasAuthorship W2286645807A5028049853 @default.
• W2286645807 hasAuthorship W2286645807A5032743242 @default.
• W2286645807 hasAuthorship W2286645807A5038533156 @default.
• W2286645807 hasAuthorship W2286645807A5046943976 @default.
• W2286645807 hasAuthorship W2286645807A5057371623 @default.
• W2286645807 hasAuthorship W2286645807A5066877678 @default.
• W2286645807 hasAuthorship W2286645807A5073277560 @default.
• W2286645807 hasAuthorship W2286645807A5080585542 @default.
• W2286645807 hasConcept C121608353 @default.
• W2286645807 hasConcept C126322002 @default.
• W2286645807 hasConcept C150903083 @default.
• W2286645807 hasConcept C185592680 @default.
• W2286645807 hasConcept C202751555 @default.
• W2286645807 hasConcept C207001950 @default.
• W2286645807 hasConcept C2777329042 @default.
• W2286645807 hasConcept C2778820342 @default.
• W2286645807 hasConcept C2779786085 @default.
• W2286645807 hasConcept C502942594 @default.
• W2286645807 hasConcept C530470458 @default.
• W2286645807 hasConcept C55493867 @default.
• W2286645807 hasConcept C71924100 @default.
• W2286645807 hasConcept C86803240 @default.
• W2286645807 hasConcept C98274493 @default.
• W2286645807 hasConceptScore W2286645807C121608353 @default.
• W2286645807 hasConceptScore W2286645807C126322002 @default.
• W2286645807 hasConceptScore W2286645807C150903083 @default.
• W2286645807 hasConceptScore W2286645807C185592680 @default.
• W2286645807 hasConceptScore W2286645807C202751555 @default.
• W2286645807 hasConceptScore W2286645807C207001950 @default.
• W2286645807 hasConceptScore W2286645807C2777329042 @default.
• W2286645807 hasConceptScore W2286645807C2778820342 @default.
• W2286645807 hasConceptScore W2286645807C2779786085 @default.
• W2286645807 hasConceptScore W2286645807C502942594 @default.
• W2286645807 hasConceptScore W2286645807C530470458 @default.
• W2286645807 hasConceptScore W2286645807C55493867 @default.
• W2286645807 hasConceptScore W2286645807C71924100 @default.
• W2286645807 hasConceptScore W2286645807C86803240 @default.
• W2286645807 hasConceptScore W2286645807C98274493 @default.
• W2286645807 hasLocation W22866458071 @default.
• W2286645807 hasOpenAccess W2286645807 @default.
• W2286645807 hasPrimaryLocation W22866458071 @default.
• W2286645807 hasRelatedWork W1512582267 @default.
• W2286645807 hasRelatedWork W1519836038 @default.
• W2286645807 hasRelatedWork W1568622226 @default.
• W2286645807 hasRelatedWork W1976538502 @default.
• W2286645807 hasRelatedWork W1993072639 @default.
• W2286645807 hasRelatedWork W2007431337 @default.
• W2286645807 hasRelatedWork W2021777935 @default.
• W2286645807 hasRelatedWork W2040879851 @default.
• W2286645807 hasRelatedWork W2048136894 @default.
• W2286645807 hasRelatedWork W2075150872 @default.
• W2286645807 hasRelatedWork W2155798001 @default.
• W2286645807 hasRelatedWork W2270238060 @default.
• W2286645807 hasRelatedWork W2728483795 @default.
• W2286645807 hasRelatedWork W2780513115 @default.
• W2286645807 hasRelatedWork W2810992100 @default.
• W2286645807 hasRelatedWork W2914371587 @default.
• W2286645807 hasRelatedWork W2916385328 @default.
• W2286645807 hasRelatedWork W2968343719 @default.
• W2286645807 hasRelatedWork W3082603054 @default.
• W2286645807 hasRelatedWork W759991424 @default.
• W2286645807 hasVolume "6" @default.
• W2286645807 isParatext "false" @default.
• W2286645807 isRetracted "false" @default.
• W2286645807 magId "2286645807" @default.
• W2286645807 workType "article" @default.